CJC-1295

CJC-1295 is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH 1-29) sold in two distinct forms that behave very differently in the body: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC (often marketed as Mod GRF 1-29). Both bind GHRH receptors on pituitary somatotroph cells to stimulate endogenous growth hormone synthesis and pulsatile release, which in turn elevates circulating IGF-1 via hepatic signalling. Everything beyond that shared mechanism depends on which form is being used.

The DAC modification is a lysine derivative (N-epsilon-3-maleimidopropionamide) attached at the C-terminus that covalently binds circulating albumin with more than 90% occupancy. This shields the peptide from renal clearance and extends half-life from roughly 30 minutes (unmodified) to 6-8 days (DAC-modified), with some reports extending to 7-10 days. The extended half-life produces sustained, dose-dependent elevation of GH and IGF-1 — the Teichman et al. 2006 Phase 1/2 study in J Clin Endocrinol Metab reported 2- to 10-fold GH elevation across 6+ days after a single dose, with IGF-1 rising 1.5- to 3-fold for 9-11 days. The Mod GRF 1-29 form, without DAC, produces shorter, sharper pulses that more closely mimic physiological GH secretion. In practice DAC suits sustained-dosing research models, while no-DAC is used where pulse fidelity matters.

Synergy with ipamorelin and other GHRPs is the rationale behind the most common off-label stacks. GHRH analogues and growth hormone releasing peptides act through distinct pituitary pathways — GHRH analogues like CJC-1295 directly stimulate somatotrophs, while GHRPs like ipamorelin bind the ghrelin receptor (GHS-R1a), suppressing somatostatin and amplifying GH release. Using the two together produces GH pulses two to five times larger than either alone in animal and limited human data, which is the biological basis for the CJC-1295 + ipamorelin combination that dominates the "growth hormone stack" protocol on peptide markets.

Human evidence is thin and concentrated. The Teichman 2006 study is the landmark human trial: subcutaneous CJC-1295 DAC at 30-250 mcg/kg in 48 healthy adults demonstrated sustained dose-dependent GH and IGF-1 elevation, good tolerability up to 60 mcg/kg weekly, no serious adverse events, and no tachyphylaxis or immunogenicity across multiple doses. ConjuChem Biotechnologies — the original developer — advanced to Phase 2 for GH deficiency and lipodystrophy but halted development after 2006 for strategic rather than safety reasons. No large Phase 3 trials followed, and CJC-1295 never reached regulatory approval. For comparison, the FDA-approved GHRH analogue tesamorelin (Egrifta, approved for HIV-associated lipodystrophy) has substantially deeper human data and clinical characterisation. CJC-1295 no-DAC has no dedicated human trials; efficacy claims are extrapolated from the DAC trial and from the GHRH class.

Reported dosing splits cleanly between research context and off-label use. Peer-reviewed research dosing for CJC-1295 DAC ranges from 30-250 mcg/kg subcutaneously, weekly or single-dose, as documented in Teichman 2006. Off-label wellness protocols for DAC typically run 1-2 mg weekly subcutaneously, either as a single injection or split into two doses. No-DAC (Mod GRF 1-29) protocols use 100-300 mcg two to three times daily subcutaneously, timed for pre-bed and pre-workout windows to align with natural GH pulse timing. The canonical stack is CJC-1295 no-DAC at 100-300 mcg paired with ipamorelin at 100-300 mcg per dose, dosed 2-3x daily; with DAC, ipamorelin 200-300 mcg nightly is a common companion. Cycle lengths of 8-12 weeks on with 4-week breaks appear in user literature. None of the wellness protocols are regulator-validated.

Safety data is as thin as the efficacy data. The Teichman trial reported good tolerability with no serious adverse events at the tested dose range. Common off-label complaints include injection-site redness, transient water retention, flushing, tingling, and the hunger/tiredness profile associated with elevated GH pulses. Theoretical concerns centre on chronic IGF-1 elevation — sustained IGF-1 is a growth signal, and there is ongoing biological debate about long-term cancer risk from persistent IGF-1 stimulation, particularly for users with family history of hormone-responsive cancers. No long-term human safety data exists for CJC-1295.

Regulatory status is the clearest part of the picture. CJC-1295 is not FDA-approved for any indication. In 2023 the FDA placed CJC-1295 on the 503A "Category 2" bulks list — the "difficult to compound" designation that restricts compounding pharmacies from producing it — with formalisation continuing through 2025 rulemaking. This effectively pushes CJC-1295 out of the compounding-pharmacy channel and back toward the research-chemical market. The World Anti-Doping Agency prohibits CJC-1295 under S2 (peptide hormones and growth factors). Anti-aging and hormone-optimisation clinics that previously prescribed compounded CJC-1295 have largely migrated to approved tesamorelin, which sits in the same GHRH-analogue mechanistic lane without the regulatory overhang.

For a consumer, the practical read is: CJC-1295 has one credible human trial from two decades ago, no approved indication, an FDA compounding restriction, and WADA prohibition. The mechanistic story and the Teichman data are scientifically real, but the evidence for long-term use at wellness-protocol doses has never been generated. If the goal is a GHRH-analogue effect in a legally defensible context, tesamorelin is the regulated alternative.